Virtual Screening

Drug discovery teams are searching for computational methods to replace costly, time-consuming physical assays in early-stage compound testing. The intent is purely informational, suggesting researchers are learning how to integrate molecular docking and machine learning models into their screening pipelines rather than comparing existing tools. The opportunity lies in building accessible, validated platforms that bridge the gap between academic methods and commercial drug development workflows.